NeuroSense Therapeutics

Historical price data

NeuroSense Therapeutics is an Israeli, NASDAQ-listed biotech focused on developing treatments for neurodegenerative diseases, with Amyotrophic Lateral Sclerosis (ALS) as its lead indication. The company's core strategy involves targeting multiple disease pathways concurrently with its fixed-dose combination drug, PrimeC, which is in a Phase IIb clinical trial (PARADIGM). NeuroSense employs biomarker analyses to demonstrate target engagement and guide development. As a micro-cap company, it represents a high-risk, high-reward opportunity contingent on the success of its lead program in a challenging therapeutic area.

A multi-target combination therapy platform focused on synergistically modulating key pathological pathways in neurodegeneration (e.g., neuroinflammation, RNA dysregulation, ferroptosis) using repurposed drugs, supported by an integrated biomarker strategy for clinical de-risking.

NeuroSense competes directly with approved ALS combinations (Amylyx's AMX0035) and a growing pipeline of late-stage targeted therapies from well-funded biopharma companies. Its differentiation hinges on PrimeC's unique dual-mechanism action and oral dosing, but it must demonstrate superior or complementary efficacy in a challenging clinical and commercial environment.